Drug · CHEMBL1643
RIBAVIRIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RIBAVIRIN. Drugs and targets, record CHEMBL1643. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1643
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Copegus, Cotronak, Rebetol, Ribapak, Ribasphere, Ribavarin, Ribavirin biopartners, Ribavirin mylan (previously ribavirin three rivers), Ribavirin teva, Ribavirin teva pharma b.v., Ribofluranosyl carboxamide, Viramid, Virazid, Virazole
- ChEMBL
- Other names
- Cotronak, NSC-163039, Ribavirin biopartners, Ribavirin mylan, Ribavirin teva, Ribavirina, Ribavirine, SCH 18908, SCH-18908, Tribavirin
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 45 diseases, from ATC, ClinicalTrials.gov, DailyMed, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase 1 | Inosine-5'-monophosphate dehydrogenase 1 inhibitor | INHIBITOR | https://conductscience.org/library/genes/3614 |
Source ChEMBL
Diseases45
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| hepatitis C virus infection | Approval | ClinicalTrials.gov and TTD | 497 | 495 | https://conductscience.org/library/drugs?q=MONDO_0005231 |
| chronic hepatitis C virus infection | Approval | DailyMed and PMDA | 178 | 146 | https://conductscience.org/library/drugs?q=MONDO_0005354 |
| cirrhosis of liver | Approval | DailyMed | 56 | 35 | https://conductscience.org/library/drugs?q=MONDO_0005155 |
| HIV infectious disease | Phase 3 | ClinicalTrials.gov | 32 | 32 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| COVID-19 | Phase 3 | ClinicalTrials.gov | 8 | 8 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| hepatocellular carcinoma | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| Lassa fever | Phase 2/3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005820 |
| hepatitis B virus infection | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005344 |
| acute myeloid leukemia | Phase 2 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| Insulin resistance | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=HP_0000855 |
1 to 10 of 45Source Open Targets
See all 45 diseasesTrials859
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00922779 | A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C | Phase 4 | 6,661 | 2016-01-20 | ribavirin | Its name | ClinicalTrials.gov |
| NCT00081770 | Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) | Phase 3 | 4,469 | 2009-10-30 | ribavirin | Its name | ClinicalTrials.gov |
| NCT00039871 | PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) | Phase 3 | 2,333 | 2008-12-11 | ribavirin | Its name | ClinicalTrials.gov |
| NCT00689390 | Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) | Phase 2/3 | 1,954 | 2015-10-06 | ribavirin | Its name | ClinicalTrials.gov |
| NCT02219490 | A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection | Phase 3 | 1,596 | 2023-04-07 | ribavirin | Its name | ClinicalTrials.gov |
| NCT00705432 | Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) | Phase 3 | 1,472 | 2011-06-14 | ribavirin | Its name | ClinicalTrials.gov |
| NCT00077636 | ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. | Phase 4 | 1,469 | 2016-01-21 | ribavirin | Its name | ClinicalTrials.gov |
| NCT00265395 | Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) | Phase 3 | 1,428 | 2009-07-08 | ribavirin | Its name | ClinicalTrials.gov |
| NCT02786537 | Study of Oral Treatments for Hepatitis C | Phase 4 | 1,275 | 2020-11-24 | ribavirin | Its name | ClinicalTrials.gov |
| NCT00394277 | A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C | Phase 4 | 1,175 | 2010-07-05 | ribavirin | Its name | ClinicalTrials.gov |
1 to 10 of 859
See all 859 trialsComparisons in its trials254
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Stage 1 Participants vs Stage 2 Participants: Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2) | 76 of 1,302 | 142 of 1,128 | 2,430 | NCT00724893 | Trial comparisons |
| Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: Number of Participants That Discontinued the LTFU Due to SAEs | 19 of 1,907 | 0 of 47 | 1,954 | NCT00689390 | Trial comparisons |
| Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: Number of Participants With Serious Adverse Events (SAEs) Reported During the LTFU | 136 of 1,907 | 2 of 47 | 1,954 | NCT00689390 | Trial comparisons |
| Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: serious adverse events | 136 of 1,907 | 2 of 47 | 1,954 | NCT00689390 | Trial comparisons |
| PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks vs PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks: serious adverse events | 34 of 731 | 47 of 728 | 1,459 | NCT00077636 | Trial comparisons |
| EBR/GZR Regimen vs SOF/LDV Regimen: Number of Participants With Adverse Events That Caused Treatment Discontinuation-EBR/GZR vs. LDV/SOF | 12 of 700 | 4 of 428 | 1,128 | NCT02786537 | Trial comparisons |
| Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment | 551 of 1,010 | 32 of 72 | 1,082 | NCT00724854 | Trial comparisons |
| Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants Who Achieved Sustained Virologic Response (SVR) | 375 of 1,010 | 24 of 72 | 1,082 | NCT00724854 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Serious Adverse Events | 175 of 517 | 155 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Development of Hepatocellular Carcinoma (HCC) | 13 of 517 | 16 of 533 | 1,050 | NCT00006164 | Trial comparisons |
1 to 10 of 254
See all 254 comparisons in its trialsPapers from its trials556
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1643
GET https://conductscience.org/api/drugs/v1/CHEMBL1643/diseases?page=2